Stephan Weidinger

Oct 16, 2023 | bpno.dk | Stephan Weidinger

oktober 2023 During EADV2023, Professor Stepan Weidinger highlighted the data on innovative mechanisms, targets, and therapeutic agents. Notably, two drugs—one founded on the OX40 ligand inhibitor and the other on the OX40 receptor—showed good outcomes in their phase 3 trials. Additionally, preliminary data on the IL13 inhibitor, Lebrikizumab, offers great promise. These advancements present dermatologists with a plethora of new treatment avenues.

Oct 4, 2023 | nature.com | Ashley Budu-Aggrey |Anna Kilanowski |Maria K Sobczyk |Suyash Shringarpure |Ruth E. Mitchell |Kadri Reis | +68 more

AbstractAtopic dermatitis (AD) is a common inflammatory skin condition and prior genome-wide association studies (GWAS) have identified 71 associated loci. In the current study we conducted the largest AD GWAS to date (discovery N = 1,086,394, replication N = 3,604,027), combining previously reported cohorts with additional available data.

Jul 19, 2023 | jamanetwork.com | Eric Simpson |Melinda Gooderham |Andreas Wollenberg |Stephan Weidinger

Errors in Figure 2 and Table 2 Footnotes Lebrikizumab With Corticosteroids for Moderate-to-Severe Atopic Dermatitis Eric L. Simpson, MD; Melinda Gooderham, MD; Andreas Wollenberg, MD; Stephan Weidinger, MD, PhD; April Armstrong, MD, MPH; Jennifer Soung, MD; Silvia Ferrucci, MD; Renata Gontijo Lima, MD; Michael M. Witte, PhD; Wen Xu, PhD; Hany ElMaraghy, MD; Chitra R.